Synaptic Biomarkers In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Synaptic biomarkers measure proteins and molecules specifically associated with synaptic function and dysfunction. They provide critical insight into synaptic loss — one of the strongest correlates of cognitive impairment in neurodegenerative diseases.
Synapses are the fundamental units of neuronal communication. In neurodegenerative diseases, synaptic loss occurs early and correlates strongly with cognitive decline. Synaptic biomarkers measure:
| Biomarker | Location | Disease Association | Sample Type |
|---|---|---|---|
| Synaptophysin | Synaptic vesicles | AD, PD, DLB | CSF, brain tissue |
| SNAP-25 | Presynaptic terminal | AD, ALS, MS | CSF |
| Synaptotagmin | Synaptic vesicles | AD, PD | CSF |
| SV2A/B/C | Synaptic vesicles | AD, epilepsy | CSF |
| Biomarker | Location | Disease Association | Sample Type |
|---|---|---|---|
| Neurogranin | Dendritic spines | AD, MCI | CSF |
| PSD-95 | Postsynaptic density | AD, FTD | CSF, brain tissue |
| SynGAP | Postsynaptic density | AD | CSF |
| GluA1/2 (AMPA) | Postsynaptic membrane | AD | CSF |
Synaptic biomarkers are particularly valuable in AD:
| Biomarker | Pathological Meaning |
|---|---|
| Aβ42/40 | Amyloid pathology |
| p-tau | Tau pathology |
| Neurogranin | Synaptic loss |
| SNAP-25 | Synaptic dysfunction |
| NfL | Neurodegeneration severity |
| Presynaptic | Postsynaptic |
|---|---|
| Synaptophysin | Neurogranin |
| SNAP-25 | PSD-95 |
| SV2A | SynGAP |
| Synaptotagmin | GluA2 |
Synaptic biomarkers used to:
Targets under investigation:
The study of Synaptic Biomarkers In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Blennow, K., et al. (2019). CSF neurogranin: a sensitive and specific biomarker for synaptic neuronal injury. Alzheimer's & Dementia, 15(7), 913-917.
[2] Lista, S., et al. (2020). Cerebrospinal fluid neurogranin as a reliable biomarker for synaptic dysfunction in Alzheimer's disease. Journal of Alzheimer's Disease, 73(1), 165-175.